2 weeks ago
15
MarketBeat
Tue, February 24, 2026 astatine 9:44 AM CST 9 min read
-
Revenue accelerated with fourth-quarter income of $59.9M and full-year gross up 20.2% to $225.2M; GAAP showed a nett nonaccomplishment but adjusted nett income and adjusted EBITDA roseate (adjusted EBITDA +41%, borderline 12.4%), and currency balances accrued to $45.5M.
-
Management hailed the December FDA BLA approval for Avance arsenic a milestone — making it the archetypal FDA‑approved biologic for peripheral nervus discontinuities with 12 years exclusivity — which the institution expects volition enactment broader payer sum (commercial sum >65% aft 2025 gains).
-
AxoGen raised $133.3M successful an upsized offering and utilized $69.7M to discontinue its word loan, and guided 2026 to astatine slightest 18% gross maturation (~$265.7M), a 74–76% gross‑margin target, and to beryllium free‑cash‑flow positive for the year.
-
Interested successful AxoGen, Inc.? Here are 5 stocks we similar better.
AxoGen (NASDAQ:AXGN) reported fourth-quarter and full-year 2025 results that absorption said marked a “financial inflection point,” citing accelerating adoption of the company’s nervus repair algorithm, improved operating leverage, and a large regulatory milestone for its Avance nervus graft.
Fourth-quarter gross was $59.9 million, up 21.3% year-over-year, portion full-year gross accrued 20.2% to $225.2 million. CEO Michael Dale said maturation was supported by “double-digit maturation crossed each 3 people markets” and expanding usage of the company’s portfolio, with Avance remaining the superior maturation driver.
→ Gold and Silver Pulled Back—Here’s Why the Bull Case Is Intact
CFO Lindsey Hartley said gross show was driven chiefly by portion measurement and mix, “in summation to price.” She besides noted the institution antecedently estimated gross was positively impacted by the discontinuation of the Avance lawsuit banal income program, but said the pull-forward interaction connected full-year results was believed to beryllium minimal.
Gross borderline declined year-over-year, successful portion owed to one-time costs tied to the FDA support of the Avance biologics licence exertion (BLA). Fourth-quarter gross borderline was 74.1% versus 76.1% a twelvemonth earlier, and full-year gross borderline was 74.3% versus 75.8% successful 2024.
→ Hinge Health’s AI Moat Might Be Its Patient Movement Data
Hartley said gross nett was negatively impacted by $1.9 million successful one-time costs successful the 4th fourth associated with the BLA approval, two-thirds of which were non-cash stock-based compensation tied to milestone vesting. Excluding one-time items, she attributed borderline unit chiefly to higher merchandise costs related to further investigating steps arsenic Avance transitioned to a biologic, partially offset by less inventory write-offs and little shipping costs pursuing the lawsuit banal program’s discontinuation.
English (CA) · 
English (US) · 
Spanish (MX) ·